Brigatinib is a medication that belongs to a class of drugs known as tyrosine kinase inhibitors. It is commonly used in the treatment of non-small cell lung cancer (NSCLC) that has a specific genetic mutation known as ALK-positive. This mutation causes the cancer cells to grow and spread rapidly, and brigatinib works by targeting and blocking the activity of the ALK protein, thereby slowing down the growth of the cancer cells.

Patients who are prescribed brigatinib should be aware of the potential side effects associated with this medication. Common side effects may include nausea, diarrhea, fatigue, and cough. It is important to report any severe or persistent side effects to your healthcare provider immediately.

It is crucial to take brigatinib exactly as prescribed by your healthcare provider. Missing doses or taking more than the recommended amount can affect the effectiveness of the medication and may increase the risk of side effects. Your healthcare provider will monitor your progress closely and may adjust your dosage as needed.

Before starting brigatinib, it is important to inform your healthcare provider about any other medications or supplements you are taking, as they may interact with brigatinib and affect its effectiveness. It is also important to discuss any pre-existing medical conditions you may have, as they may impact your ability to take brigatinib safely.

Overall, brigatinib is a valuable medication in the treatment of ALK-positive NSCLC, and when taken as directed and under the supervision of a healthcare provider, it can help improve outcomes for patients with this type of cancer.